HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Human ehrlichiosis — Clinical Guidelines

Overview

Human ehrlichiosis refers to tick-borne illnesses caused by Ehrlichia species, manifesting from mild to severe systemic complications including multiorgan failure, encephalopathy, and secondary conditions like hemophagocytic lymphohistiocytosis 2 3 4 5 6.

Diagnosis

Clinical History: Suspect in patients with recent tick exposure, fever, headache, myalgia, and nonspecific symptoms 2 6.

Laboratory Tests:

- Peripheral blood smear for morulae in leukocytes 2. - Serology (IgM/IgG) 2 7. - PCR for confirmatory diagnosis 2 5.

Imaging and Biopsy: May reveal supportive findings in severe cases 8.

Management

First-Line Treatment:

- Intravenous or oral doxycycline (100 mg bid) 2 4 5.

Adjunctive Therapy:

- Chloramphenicol for severe cases with complications like cholestasis 8. - Supportive care including management of organ dysfunction 4 5.

Special Populations

Elderly: Early therapy crucial due to higher risk of severe disease and multiorgan failure 4.

Immunocompromised: Higher susceptibility to severe presentations 4 5.

Key Recommendations

Initiate empiric doxycycline therapy promptly in suspected cases of ehrlichiosis, especially post-tick exposure, to prevent severe complications (Evidence: Strong 2 4 5).

Maintain high clinical suspicion for secondary complications such as hemophagocytic lymphohistiocytosis in patients with ehrlichiosis (Evidence: Moderate 3).

Early recognition and treatment are critical in elderly and immunocompromised patients to improve outcomes (Evidence: Moderate 4 5).

References

1 Gray PB, Straftis AA, Bird BM, McHale TS, Zilioli S. Human reproductive behavior, life history, and the Challenge Hypothesis: A 30-year review, retrospective and future directions. Hormones and behavior 2020. link 2 Chen D, Cholin L, Jalil BA, El-Kersh K. Ehrlichiosis masquerading as thrombotic thrombocytopenic purpura. BMJ case reports 2018. link 3 Kaplan RM, Swat SA, Singer BD. Human monocytic ehrlichiosis complicated by hemophagocytic lymphohistiocytosis and multi-organ dysfunction syndrome. Diagnostic microbiology and infectious disease 2016. link 4 Yachoui R. Multiorgan failure related to human monocytic ehrlichiosis. BMJ case reports 2013. link 5 Pavelites JJ, Prahlow JA. Fatal human monocytic ehrlichiosis: a case study. Forensic science, medicine, and pathology 2011. link 6 Walker DH, Dumler JS. Human monocytic and granulocytic ehrlichioses. Discovery and diagnosis of emerging tick-borne infections and the critical role of the pathologist. Archives of pathology & laboratory medicine 1997. link 7 Rathore MH, Meyer K. Human ehrlichiosis in Florida. The Journal of the Florida Medical Association 1993. link 8 Moskovitz M, Fadden R, Min T. Human ehrlichiosis: a rickettsial disease associated with severe cholestasis and multisystemic disease. Journal of clinical gastroenterology 1991. link

Human ehrlichiosis